




Do Multimodal Ocular Biomarkers Have Added Value To Blood Biomarkers For Alzheimer’s Disease And Related Dementias? The CIRCAME-Eye Study

Frank van der Heide^{1,2}, Aude Couturier^{3,4,5}, Dan Milea¹, Sophie Bonnin^{1,3,4,5}, Aline Dugravot², Rose-Marie Sadon³, Claire Paquet⁷, Severine Sabia⁴.

¹Adolphe de Rothschild Foundation hospital (HFAR), Paris, France, ²EpiAgeing, INSERM, Paris, France, ³French Image Reading Center, HFAR, Paris, France; ⁴Ophthalmology Department, Rothschild Foundation Hospital, Paris, France; ⁵Ophthalmology University Paris Cité, Ophthalmology Department, Assistance Publique - Hôpitaux de Paris, Paris, France; ⁶ Université Paris Cité, GHU APHP Nord Lariboisière Fernand Widal, Centre de Neurologie Cognitive, Paris, France.

The CIRCAME-EYE Study aspires to determine whether retinal imaging biomarkers (OCT,OCT-A, widefield fundus photography) may provide scalable biomarkers for Alzheimer’s disease and related dementias.

INTRODUCTION	METHODS	RESULTS	CONCLUSIONS	SUPPORT
Scalable biomarkers for Alzheimer’s disease and related dementia (ADRD)and mild cognitive impairment (MCI) are needed Retinal imaging may provide scalable biomarkers The added value of retinal imaging beyond known risk factors remains unknown. <u>Objective:</u> Determine the added value of retinal imaging biomarkers beyond known risk factors for ADRD	The CIRCAME-EYE study is a prospectively designed cohort of ~800 patients from a French memory clinic (Fernand Widal, Paris) <u>Retinal imaging:</u> -widefield fundus photos -OCT & OCT-A  <u>Risk factors:</u> -sociodemographic -lifestyle -cardiovascular -apolipoprotein E4 <u>Blood biomarkers</u> -pTau-217	511 patients have been included.  Figure 1 CIRCAME-EYE study population Inclusion will continue up till December 2026.	CIRCAME-EYE study is a prospectively designed study which aims to include ~ 800 patients by December 2026 Multimodal analyses will be conducted using known retinal biomarkers (e.g. vessel width) and artificial intelligence-based methods Retinal imaging biomarkers may provide scalable biomarkers for ADRD and MCI	 ROTHSCHILD FOUNDATION HOSPITAL HEAD AND NECK EXPERTISE  FONDATION VAINCRE ALZHEIMER Prévenir, soigner, guérir  ALZHEIMER'S ASSOCIATION AAIC>26